Janssen ventures into antithrombin antibody-based drugs

Janssen Pharmaceuticals acquired a university spinout company that develops an antithrombin antibody, adding another potential therapy to its portfolio.

Janssen makes the novel oral anticoagulant rivaroxaban (Xarelto), a factor Xa inhibitor that received FDA approved in 2012 as a treatment for deep vein thrombosis and pulmonary embolism and to reduce the risk of recurrences. The drug previously was cleared in the U.S. to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.

Janssen purchased XO1 Limited, a biopharmaceutical company that developed the antithrombin antibody ichorcumab. Researchers from Addenbrooke Hospital and Cambridge University in the U.K. invented and designed the drug, which is a recombinant human antibody that targets thrombin. Unlike other anticoagulants, ichorcumab is said to provide anticoagulation properties yet not increase the risk of bleeding.

Neither Janssen nor X01 disclosed financial terms for the deal. Johnson & Johnson Innovation in London facilitated in agreement. Janssen Pharmaceuticals is a Johnson & Johnson company.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup